Vaccination strategies: An overview

Vaccine

Volumn 21, Issue SUPPL. 2, 2003, Pages

  Del Giudice, Giuseppe ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

Dendritic cells; Immunological memory; Vaccines

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; HAPTEN; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; PROTEIN E6; PROTEIN E7; PROTEIN PT; PROTEIN TT; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; BORDETELLA PERTUSSIS; CELL FUNCTION; CELLULAR IMMUNITY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMPIRICISM; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOLOGICAL MEMORY; INFANCY; INFECTION; MICROBIOLOGY; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; NEWBORN CARE; NEWBORN PERIOD; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION; VIRUS INFECTION; WART VIRUS;

EID: 0038325753     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00205-6     Document Type: Review

References (43)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21th century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev. 13:2000;302-317.
2. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:2002;717-722.
3. Plotkin S.A. Immunological correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20:2001;63-75.
4. Avery O., Goebel W. Chemo-immunological studies on conjugated carbohydrate-proteins. Part II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 50:1929;533-550.
5. Rescigno M., Urbano M., Valzasina B.et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nature Immunol. 2:2001;361-367.
6. Neutra M.R., Mantis N.J., Kraehenbuhl J.P. Collaboration of epithelial cells with organized lymphoid tissues. Nature Immunol. 2:2001;1004-1009.
7. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109:2002;1516-1526.
8. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nature Rev. Immunol. 1:2001;209-219.
9. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell. 106:2001;255-258.
10. Janeway C.A. Jr., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216.
11. Del Giudice G, Rappuoli R. Adjuvants and subunit vaccines. In: Kaufmann S, Steward M, editors. Topley and Wilson's microbiology and microbial infections. 10th ed. London: Arnold; 2003, in press.
12. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Rev. Immunol. 2:2002;251-262.
13. Siegrist C.A. Neonatal and early life vaccinology. Vaccine. 19:2001;3331-3346.
14. Boraschi D, Tagliabue A, Martin MU, Rappuoli R. Mechanisms of innate immunity in pathogen-host interaction and its exploitation for novel mucosal immunisation strategies. Vaccine 2003, in press.
15. DC STRATEGIES. Immunological mechanisms of T cell activation by dendritic cells: a novel strategy for immune intervention. QLK2-CT-2000-00470. Web page: http://dbs.cordis.lu/fep-cgi/srchidadb?ACTION=D&SESSION= 113072003-1-22&DOC=1&TBL=EN_PROJ&RCN=EP_DUR:36&CALLER= PROJ_LIFE .
16. Rescigno M., Granucci F., Citterio S., Foti M., Ricciardi-Castagnoli P. Coordinated events during bacteria-induced DC maturation. Immunol. Today. 20:1999;200-203.
17. Ricciardi-Castagnoli P., Granucci F. Interpretation of the complexity of innate immune responses by functional genomics. Nature Rev. Immunol. 2:2002;1-8.
18. Granucci F., Vizzardelli C., Pavelka N.et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nature Immunol. 2:2001;882-888.
19. Granucci F., Andrews D.M., Degli Esposti M.A., Ricciardi-Castagnoli P. IL-2 mediates adjuvant effect of dendritic cells. Trends Immunol. 23:2002;169-171.
20. Van der Burg S.H., Ressing M.E., Kwappenberg K.M.et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer. 91:2001;612-618.
21. Rudolf M.P., Man S., Melief C.J., Sette A., Kast W.M. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin. Cancer Res. 7(Suppl. 3):2001;788s-795s.
22. Evans M., Borysiewicz L.K., Evans A.S.et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167:2001;5420-5428.
23. De Jong A., van der Burg S.H., Kwappenberg K.M.et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62:2002;472-479.
24. Van der Burg S.H., Kwappenberg K.M., O'Neill T.et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 19:2001;3652-3660.
25. PROTARVAC. Development of prophylactic and therapeutic vaccines optimised for cellular processing and presentation to T lymphocytes and targeted to professional antigen presenting cells. QLK2-CT-2001-01167. Web page: http://dbs.cordis.lu/fep-cgi/srchidadb?ACTION=D&SESSION= 108992003-1-22&DOC=1&TBL=EN_PROJ&RCN=EP_DUR:36&CALLER= PROJ_LIFE .
26. Schirmbeck R., Reimann J. Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class I-restricted peptide repertoire. Mol. Immunol. 39:2002;249-259.
27. Fruci D., Niedermann G., Butler R.H., van Endert P.M. Efficient MHC class I-independent amino-terminal trimming of epitope precursor peptides in the endoplasmic reticulum. Immunity. 15:2001;467-476.
28. CTLATVAX. Priming protective MHC class I-restricted T cell immunity by novel vaccine delivery strategies that target alternative epitope repertoires. QLK2-CT-2002-00700. Web page: http://dbs.cordis.lu/fep-cgi/srchidadb?ACTION=D&SESSION= 114692003-1-22&DOC=1&TBL=EN_PROJ&RCN=EP_DUR:36&CALLER= PROJ_LIFE .
29. Saveanu L., Fruci D., van Endert P.M. Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. Mol. Immunol. 39:2002;203-215.
30. MEMOVAX. Immunological memory and vaccination. QLK2-CT-2001-01205. Web page: http://dbs.cordis.lu/fep-cgi/srchidadb?ACTION=D&SESSION= 105272003-1-22&DOC=1&TBL=EN_PROJ&RCN=EP_DUR:36&CALLER= PROJ_LIFE .
31. Sallusto F., Mackay C.R., Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:2000;593-620.
32. Geginat J., Sallusto F., Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naïve, central memory, and effector memory CD4+ T cells. J. Exp. Med. 194:2001;1711-1719.
33. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potential and effector functions. Nature. 401:1999;708-712.
34. Messi M., Giacchetto I., Nagata K., Lanzavecchia A., Natoli G., Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human Th1 and Th2 lymphocytes. Nature Immunol. 4:2003;78-86.
35. Siegrist CA. Immunological requirements for vaccines to be used in early life. In: Bloom BR, Lambert PH, editors. The vaccine book. Amsterdam: Academic Press; 2003. p. 73-83.
36. NEOVAC-EC. Improving vaccination in early life.QLK2-CT-1999-00429. Web page: http://dbs.cordis.lu/fep-cgi/srchidadb?ACTION=D&SESSION= 106492003-1-22&DOC=1&TBL=EN_PROJ&RCN=EP_DUR:36&CALLER= PROJ_LIFE .
37. Dadaglio G., Sun C.M., Lo-Man R., Siegrist C.A., Leclerc C. Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells. J. Immunol. 168:2002;2219-2224.
38. Goriely S., Vincart B., Stordeur P.et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J. Immunol. 166:2001;2141-2146.
39. Tonon S., Goriely S., Aksoy E.et al. Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. Eur. J. Immunol. 32:2002;3118-3125.
40. Jakobsen H., Bjarnarson S., Del Giudice G., Moreau M., Siegrist C.A., Jonsdottir I. Intranasal immunization with pneumococcal conjugate vaccines with LTK63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immunol. 70:2002;1443-1452.
41. Roduit C., Bozzotti P., Mielcarek N.et al. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect. Immunol. 70:2002;3521-3528.
42. Schallert N., Pihlgren M., Kovarik J.et al. Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines. Eur. J. Immunol. 32:2002;752-760.
43. Culley F.J., Pollott J., Openshaw P.J. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J. Exp. Med. 196:2002;1381-1386.